• Explore /
  • Poster
  • / A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.

A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.

Abstract Video & Slides Poster

Authors

null

Ana Baramidze

Todua Clinic, Tbilisi, Georgia

Ana Baramidze , Miranda Gogishvili , Tamta Makharadze , Mariam Zhvania , Khatuna Vacharadze , John Crown , Tamar Melkadze , Omid Hamid , Georgina V. Long , Caroline Robert , Mario Sznol , Hector Martinez-Said , Jayakumar Mani , Usman Chaudhry , Mark Salvati , Israel Lowy , Matthew G. Fury , Giuseppe Gullo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05352672

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9602)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9602

Abstract #

TPS9602

Poster Bd #

360a

Abstract Disclosures

Similar Posters

First Author: Nikhil I. Khushalani

First Author: Daniel Olson

First Author: Timothy J. Panella

First Author: Inge Marie Svane